IGBA Seeks To Underline Value And Access
Global Industry Association Chair Explains How It Is Making Its Message Heard
Speaking with Generics Bulletin at the IGBA’s annual conference in February, chair Jonathan Kimball explained how the association is conveying the value of generics and biosimilars to international industry stakeholders.
You may also be interested in...
Looking back over the first quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from January to March that include the launch of the first US Humira biosimilar, new leadership at the top of some of the industry’s biggest players, annual results and strategy updates, and multiple major industry conferences – as well as the launch of our annual awards.
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.
The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.